MX338595B - Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. - Google Patents
Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.Info
- Publication number
- MX338595B MX338595B MX2013006066A MX2013006066A MX338595B MX 338595 B MX338595 B MX 338595B MX 2013006066 A MX2013006066 A MX 2013006066A MX 2013006066 A MX2013006066 A MX 2013006066A MX 338595 B MX338595 B MX 338595B
- Authority
- MX
- Mexico
- Prior art keywords
- lupus
- jak2
- inhibitor
- treatment
- janus kinase
- Prior art date
Links
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 2
- 102000006503 Janus Kinase 2 Human genes 0.000 title 1
- 108010019437 Janus Kinase 2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar lupus en un sujeto, que comprende la etapa de administrar al sujeto del Compuesto A (Ver Fórmula) Compuesto A.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42005310P | 2010-12-06 | 2010-12-06 | |
US42096710P | 2010-12-08 | 2010-12-08 | |
PCT/US2011/063427 WO2012078574A2 (en) | 2010-12-06 | 2011-12-06 | Janus kinase 2 (jak2) inhibitor for the treatment of lupus |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013006066A MX2013006066A (es) | 2013-12-02 |
MX338595B true MX338595B (es) | 2016-04-25 |
Family
ID=46207678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006066A MX338595B (es) | 2010-12-06 | 2011-12-06 | Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. |
Country Status (8)
Country | Link |
---|---|
US (1) | US9023853B2 (es) |
EP (1) | EP2648728B1 (es) |
JP (1) | JP6033230B2 (es) |
CA (1) | CA2818941A1 (es) |
ES (1) | ES2582465T3 (es) |
HK (1) | HK1189822A1 (es) |
MX (1) | MX338595B (es) |
WO (1) | WO2012078574A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012078504A1 (en) * | 2010-12-06 | 2012-06-14 | Cephalon, Inc. | TREATMENT OF CHRONIC INFLAMMATION WITH A 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVE |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009029998A1 (en) * | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CN102131390A (zh) * | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | 三唑并吡啶jak抑制剂化合物和方法 |
WO2009155551A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
GB0812198D0 (en) * | 2008-07-03 | 2008-08-13 | Xipower Ltd | Improvements in and relating to battery management |
WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
WO2010141796A2 (en) * | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
WO2012078504A1 (en) * | 2010-12-06 | 2012-06-14 | Cephalon, Inc. | TREATMENT OF CHRONIC INFLAMMATION WITH A 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVE |
-
2011
- 2011-12-06 ES ES11846725.7T patent/ES2582465T3/es active Active
- 2011-12-06 EP EP11846725.7A patent/EP2648728B1/en active Active
- 2011-12-06 WO PCT/US2011/063427 patent/WO2012078574A2/en active Application Filing
- 2011-12-06 CA CA2818941A patent/CA2818941A1/en not_active Abandoned
- 2011-12-06 MX MX2013006066A patent/MX338595B/es active IP Right Grant
- 2011-12-06 JP JP2013542251A patent/JP6033230B2/ja active Active
-
2013
- 2013-06-06 US US13/911,447 patent/US9023853B2/en active Active
-
2014
- 2014-03-26 HK HK14102962.4A patent/HK1189822A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2818941A1 (en) | 2012-06-14 |
JP2013544292A (ja) | 2013-12-12 |
US20140024655A1 (en) | 2014-01-23 |
ES2582465T3 (es) | 2016-09-13 |
US9023853B2 (en) | 2015-05-05 |
EP2648728A4 (en) | 2014-06-04 |
JP6033230B2 (ja) | 2016-11-30 |
HK1189822A1 (zh) | 2014-06-20 |
MX2013006066A (es) | 2013-12-02 |
WO2012078574A2 (en) | 2012-06-14 |
WO2012078574A9 (en) | 2012-08-16 |
EP2648728A2 (en) | 2013-10-16 |
EP2648728B1 (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX339873B (es) | Inhibidores de serina/treonina cinasa. | |
TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
MY165620A (en) | Cyclopropylamines as lsd1 inhibitors | |
MX340756B (es) | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. | |
MY179607A (en) | Combinations of akt inhibitor compounds and abiraterone, and methods of use | |
EA201890768A2 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
MY162933A (en) | Chemical compounds | |
MX2010002312A (es) | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. | |
UA115983C2 (uk) | Інгібітори днк-пк | |
IN2012DN03883A (es) | ||
WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
MX2009005649A (es) | Tratamiento para mieloma multiple. | |
NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
PH12015501038A1 (en) | Inhibitors of iap | |
MX2015000980A (es) | Inhibidores de aril lactama cinasa. | |
UA115455C2 (uk) | Спосіб одержання сполук для застосування при лікуванні раку | |
MX2013011333A (es) | Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. | |
MX343968B (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
WO2013037943A8 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
MX2013006066A (es) | Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. | |
MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
UA42783U (ru) | Способ лечения дисбактериоза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |